论文部分内容阅读
目的 监测肺结核菌阳性病人的起始耐药情况,评价抗痨效果和结核病控制现状。方法 按DOTS方案进行药敏试验,监测新发病例痰培养结核菌阳性的抗痨药物敏感性。结果1996～2001年每年起始耐药率在10.9％～30.4％范围内.平均起始耐药率为21.5％(105/489);70～岁组起始耐药率最低(10.5％),50～岁组起始耐药率最高(27.1％)。异烟肼(H)、利福平(R)、链霉素(S)、乙胺丁醇(E)的耐药率依次为:H>S>R=E,以H耐药率最高17.8％(87/489);而同时以H、R、E、S的4种药物耐药率仅为1.0％(5/489)。结论 临床抗痨药物耐药情况严重,建议使用抗结核复合剂,严格DOTS治疗,以降低结核病耐药并控制结核病。
Objective To monitor the initial drug resistance of patients with positive pulmonary tuberculosis and to evaluate the anti-tuberculosis effect and the status of tuberculosis control. Methods According to the DOTS protocol, drug sensitivity test was conducted to detect the susceptibility of anti-tuberculosis drugs in newly diagnosed cases of sputum culture. Results The initial resistance rate was between 10.9% and 30.4% from 1996 to 2001. The average initial resistance rate was 21.5% (105/489). The initial resistance rate was the lowest (10.5%) in the 70 ~ The initial resistance rate of 50 ~ age group was the highest (27.1%). The resistance rates of isoniazid (H), rifampin (R), streptomycin (S) and ethambutol (E) were as follows: H> S> R = % (87/489). Meanwhile, the resistance rates of the four drugs to H, R, E and S were only 1.0% (5/489). Conclusion Clinical anti-tuberculosis drug resistance is serious, it is recommended to use anti-TB compound, strict DOTS treatment to reduce drug resistance and control tuberculosis.